Anti-FVIII antibody profiles are closely linked to inhibitor levels in cases of acquired hemophilia A. An exercise in antifactor VIII (FVIII) antibody profiling showed distinct patterns in acquired ...

A patient presented with task-related isolated transient weakness in her right hand, which started 15 years before and lasted for 9 years without worsening or improvement. Distal myasthenia gravis (MG ...

Approximately 31% of dermatologists reported difficulty with flare management, citing slow response to treatment (63%) and lack of flare prevention (66%) as key challenges. There is an urgent need for ...

For the last 3 years, the PBC Foundation, based in Edinburgh, Scotland, has conducted an annual summit that addresses the challenges and potential remedies for those living with primary biliary ...

Researchers from Italy presented the rare case of a patient with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) who developed aseptic meningitis and ...

Participants who developed certain malignancies such as Richter’s Syndrome and therapy-related myeloid cancers had the poorest prognosis. Individuals with chronic lymphocytic leukemia (CLL) or small ...

Valoctocogene roxaparvovec is safe and effective in treating hemophilia A across a number of efficacy parameters, including improving health-related quality of life. Valoctocogene roxaparvovec gene ...

Rare Disease Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient ...

Overall, 80.9% of patients were in complete remission 1 year after diagnosis irrespective of GPA or MPA cases (79.7% vs 83.8%, respectively). The therapeutic armamentarium for individuals with ...

The primary goals of AI personalization were to improve onboarding, boost medication initiation and adherence, and enhance physician follow-up. AllazoHealth’s artificial intelligence (AI)-powered ...

The study consists of administering doxecitine and doxribtimine orally, in 3 equal doses, every 6 to 8 hours. An upcoming study will investigate the therapeutic profile and characteristics of ...

Yiannis Papazoglou is one of only 40 people in the world with a mutation of the IRF2BPL gene. Foundation Aims to Help Patients With Rare Diseases—Even Before They’re Recognized The Undiagnosed ...